English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Biogen to Launch Study of Higher Spinraza Dose in Patients With Later Onset SMA
Biogen announced it intends to initiate a global phase 3b study to investigate clinical outcomes and safety of a higher dose of Spinraza in patients with later onset spinal muscular atrophy previously treated with Evrysdi.
“We believe that lower drug exposure may be contributing to less-than-optimal treatment outcomes for some patients treated with Evrysdi [risdiplam, Roche],” Maha Radhakrishnan, MD, chief medical officer at Biogen, said in a press release. “The ASCEND study seeks to understand if [Spinraza (nusinersen, Biogen)] may address that unmet medical need and will help inform the future of [spinal muscular atrophy (SMA)] treatment, with the hope of improving patients’ outcomes for the long term.”
Data from prior studies suggested risdiplam exposure decreases as age and weight increase, with adults exhibiting an approximate 40% reduction in drug concentration compared with infants. Upon a patient reaching 20 kg, risdiplam’s dosing is capped at 5 mg.
BookmarkRelated Content
-
Every Day You Don’t Lose, You Are WinningJennifer Summers, 35, is an optimistic, ...
-
Assessment of Cerebral Spinal Fluid Biomarkers and microRNA-Mediated Disease Mechanisms in Spinal Muscular Atrophy P...Cerebral spinal fluid (CSF) is a promisi...
-
Despite Taking Spinraza, SMA Type 1 Children Show Nonmotor ProblemsDespite its well-reported benefits in mo...
-
Lunch & Learn: Gene Therapy for SMAhttps://www.youtube.com/watch?v=YFEMR1ZH...
-
Combination Therapy With Nusinersen and Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy Type ISpinal muscular atrophy (SMA) is a neuro...
-
Your Guide to Spinal Muscular Atrophyhttps://simedhealth.com/sites/default/fi...
-
Spinal Muscular Atrophy Fact SheetWhat is spinal muscular atrophy?Spinal m...
Powered by
In partnership with
